{"id":"desvenlafaxine-succinate-sustained-release","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Nausea"},{"rate":"10-15","effect":"Dizziness"},{"rate":"10-15","effect":"Headache"},{"rate":"10-15","effect":"Insomnia"},{"rate":"5-10","effect":"Somnolence"},{"rate":"5-10","effect":"Hypertension"},{"rate":"5-10","effect":"Sexual dysfunction"},{"rate":"5-10","effect":"Sweating"},{"rate":"5-10","effect":"Dry mouth"}]},"_chembl":{"chemblId":"CHEMBL1201728","moleculeType":"Small molecule","molecularWeight":"381.47"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Desvenlafaxine is the active metabolite of venlafaxine and functions as a serotonin-norepinephrine reuptake inhibitor (SNRI). By blocking the reuptake transporters for both serotonin and norepinephrine, it increases the concentration of these neurotransmitters in the synaptic cleft, enhancing their signaling and producing antidepressant and anxiolytic effects. The sustained-release formulation provides steady-state drug levels with once-daily dosing.","oneSentence":"Desvenlafaxine inhibits the reuptake of serotonin and norepinephrine in the central nervous system, increasing their synaptic availability.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:44:17.939Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Major depressive disorder"},{"name":"Generalized anxiety disorder"},{"name":"Social anxiety disorder"},{"name":"Panic disorder"},{"name":"Vasomotor symptoms associated with menopause"}]},"trialDetails":[{"nctId":"NCT06270433","phase":"NA","title":"Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets Versus Desvenlafaxine Succinate Sustained-release Tablets Targeting Anhedonia in Patients With Major Depression Disorder","status":"RECRUITING","sponsor":"Jiangsu Province Nanjing Brain Hospital","startDate":"2024-02-19","conditions":"Anhedonia","enrollment":80},{"nctId":"NCT00406640","phase":"PHASE3","title":"Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) vs. Escitalopram in Postmenopausal Women","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2006-12","conditions":"Depression, Depressive Disorder, Depressive Disorder, Major","enrollment":595},{"nctId":"NCT01050218","phase":"PHASE3","title":"Study Evaluating the Long-Term Safety of Desvenlafaxine Succinate Sustained-Release (DVS SR) in Subjects With Pain Associated With Diabetic Peripheral Neuropathy","status":"TERMINATED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2006-07","conditions":"Diabetic Neuropathy, Painful","enrollment":237},{"nctId":"NCT04364997","phase":"PHASE3","title":"Study of Desvenlafaxine in Treating Major Depressive Disorder.","status":"COMPLETED","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2020-06-18","conditions":"Major Depressive Disorder","enrollment":420},{"nctId":"NCT00669110","phase":"PHASE2","title":"Study Evaluating Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR) In The Treatment Of Child and Adolescent Outpatients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2008-05","conditions":"Depressive Disorder, Major Depressive Disorder","enrollment":40},{"nctId":"NCT01372150","phase":"PHASE3","title":"A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-11-17","conditions":"Major Depressive Disorder","enrollment":340},{"nctId":"NCT00831415","phase":"PHASE3","title":"Study Evaluating Long-Term Safety of Desvenlafaxine Succinate Sustained Release With Japanese Adult Subjects in Major Depressive Disorder (MDD)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-03","conditions":"Major Depressive Disorder","enrollment":304},{"nctId":"NCT01371708","phase":"PHASE3","title":"A 6-Month Extension Study To The B2061032 Study To Evaluate The Safety, Tolerability, And Efficacy Of DVS SR In The Treatment Of Child And Adolescent Outpatients With MDD","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-02-02","conditions":"Major Depressive Disorder","enrollment":283},{"nctId":"NCT01371734","phase":"PHASE3","title":"A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-08","conditions":"Major Depressive Disorder","enrollment":363},{"nctId":"NCT01371721","phase":"PHASE3","title":"A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-02","conditions":"Major Depressive Disorder","enrollment":269},{"nctId":"NCT00887224","phase":"PHASE3","title":"Relapse Prevention Study Of Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-06","conditions":"Major Depressive Disorder","enrollment":874},{"nctId":"NCT01432457","phase":"PHASE4","title":"Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-10","conditions":"Major Depressive Disorder","enrollment":924},{"nctId":"NCT01977378","phase":"PHASE2, PHASE3","title":"A Study of Sustained-Release Desvenlafaxine Hydrochloride for the Treatment of Major Depressive Disorder","status":"UNKNOWN","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","startDate":"2013-10","conditions":"Major Depressive Disorder","enrollment":300},{"nctId":"NCT00445679","phase":"PHASE3","title":"Paroxetine-referenced Study Evaluating Three Doses of DVS SR in Outpatients With MDD","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2007-07","conditions":"Depressive Disorder, Major","enrollment":807},{"nctId":"NCT00696787","phase":"PHASE2","title":"A Study Evaluating Desvenlafaxine Sustained Release (DVS SR) in Adult Female Outpatients With Fibromyalgia","status":"TERMINATED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2008-06","conditions":"Fibromyalgia","enrollment":125},{"nctId":"NCT00818155","phase":"PHASE1","title":"Study Evaluating the Safety, Tolerability and Pharmacokinetics of Desvenlafaxine Succinate SR in Healthy Chinese Male and Females","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2009-01","conditions":"Healthy","enrollment":36},{"nctId":"NCT00369343","phase":"PHASE3","title":"Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) Versus Placebo in Peri- and Postmenopausal Women","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2006-09","conditions":"Depression, Depressive Disorder, Depressive Disorder, Major","enrollment":381},{"nctId":"NCT01121484","phase":"PHASE4","title":"Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) In The Treatment Of Peri- And Postmenopausal Women With Major Depressive Disorder (DVS 3364)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-06","conditions":"Major Depressive Disorder","enrollment":439},{"nctId":"NCT00384033","phase":"PHASE3","title":"Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) In The Treatment Of Major Depressive Disorder","status":"COMPLETED","sponsor":"Pfizer","startDate":"2006-09","conditions":"Depressive Disorder, Major","enrollment":638},{"nctId":"NCT01056289","phase":"PHASE4","title":"Study Comparing Discontinuation Symptoms Of DVS SR In Subjects With Major Depressive Disorder (MDD)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-03","conditions":"Major Depressive Disorder","enrollment":480},{"nctId":"NCT01190514","phase":"PHASE1","title":"Phase 1 Study To Test the Bioequivalence Between Two 25 mg Tablets vs. One 50 mg Tablet Under Fast/Fed Condition and Evaluate Food Effect of Desvenlafaxine Succinate Sustained Release (DVS SR)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-09","conditions":"Depression - Major Depressive Disorder","enrollment":41},{"nctId":"NCT01443208","phase":"PHASE1","title":"Pharmacokinetics and Safety of Desvenlafaxine in Korean Healthy Subjects Following Single and Multiple Oral Doses of Desvenlafaxine Succinate Sustained Release Tablet","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-11","conditions":"Major Depressive Disorder","enrollment":36},{"nctId":"NCT01188668","phase":"PHASE4","title":"Open Label Drug Interaction Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) 100mg On The Pharmacokinetics Of Aripiprazole When Coadministered To Healthy Subjects","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-08","conditions":"Pharmacokinetics, Cytochrome P-450 CYP2D6, CYP3A4 Protein, Human","enrollment":38},{"nctId":"NCT01189500","phase":"PHASE4","title":"Open-Label Drug Interaction Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) 100mg On The Pharmacokinetics Of Tamoxifen When Coadministered To Healthy Post-Menopausal Female Subjects","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-08","conditions":"Pharmacokinetics","enrollment":30},{"nctId":"NCT00401245","phase":"PHASE3","title":"The Effect Of Dose Titration And Dose Tapering On The Tolerability Of DVS SR In Women With Vasomotor Symptoms","status":"COMPLETED","sponsor":"Pfizer","startDate":"2006-12","conditions":"Vasomotor Symptoms","enrollment":500},{"nctId":"NCT00283842","phase":"PHASE3","title":"Study Evaluating Desvenlafaxine Succinate Sustained-release (DVS SR) in Adult Outpatients With Pain Associated With Diabetic Peripheral Neuropathy","status":"TERMINATED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2006-03","conditions":"Diabetic Neuropathies, Pain","enrollment":408},{"nctId":"NCT00683800","phase":"PHASE3","title":"Study Evaluating The Safety And Efficacy Of Desvenlafaxine Succinate For Vasomotor Symptoms In Menopausal Women","status":"COMPLETED","sponsor":"Pfizer","startDate":"2008-06","conditions":"Vasomotor Symptoms","enrollment":2186},{"nctId":"NCT00952653","phase":"PHASE4","title":"Study Evaluating the Effect of Desvenlafaxine on the Pharmacokinetics of Midazolam","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-06","conditions":"Major Depressive Disorder","enrollment":28},{"nctId":"NCT00798707","phase":"PHASE3","title":"Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) in the Treatment of Major Depressive Disorder","status":"COMPLETED","sponsor":"Pfizer","startDate":"2008-12","conditions":"Major Depressive Disorder","enrollment":709},{"nctId":"NCT00863798","phase":"PHASE3","title":"Study Evaluating Desvenlafaxine Succinate Sustained Release In Adults With Major Depressive Disorder","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2009-04","conditions":"Major Depressive Disorder","enrollment":682},{"nctId":"NCT00824291","phase":"PHASE3","title":"Study Evaluating Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2009-02","conditions":"Depressive Disorder, Major","enrollment":437},{"nctId":"NCT00619619","phase":"PHASE2","title":"Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) In The Treatment Of Child And Adolescent Outpatients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2008-02","conditions":"Depression, Major Depressive Disorder","enrollment":59},{"nctId":"NCT01221935","phase":"","title":"Retrospective Study Evaluating The Current Utilization Of Desvenlafaxine Succinate Sustained-Release (Pristiq) Among Psychiatrists And Primary Care Physicians In The Treatment Of Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-09","conditions":"Major Depressive Disorder","enrollment":2701},{"nctId":"NCT00727064","phase":"PHASE1","title":"Study Evaluating the Pharmacokinetics of Venlafaxine Extended-Release (ER) and Desvenlafaxine Succinate Sustained-Release (DVS SR) 50 mg in Healthy Subjects","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2008-06","conditions":"Healthy","enrollment":14},{"nctId":"NCT00277823","phase":"PHASE3","title":"Study Evaluating Desvenlafaxine Sustained-Release (DVS-SR) in Adult Outpatients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2006-02","conditions":"Major Depressive Disorder","enrollment":480},{"nctId":"NCT00397176","phase":"PHASE1","title":"Study Evaluating Safety, Tolerability, and PK of DVS SR in Healthy Japanese Women","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2006-11","conditions":"Vasomotor Symptoms","enrollment":32},{"nctId":"NCT00456898","phase":"PHASE1","title":"Study Evaluating the Potential of DVS SR to Inhibit the CYP2D6 Pathway","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2007-01","conditions":"Depressive Disorder, Major, Diabetic Neuropathies, Fibromyalgia","enrollment":40},{"nctId":"NCT00424892","phase":"PHASE2, PHASE3","title":"Study Evaluating DVS SR in Patients With Fibromyalgia Syndrome","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"","conditions":"Fibromyalgia","enrollment":600},{"nctId":"NCT00440427","phase":"PHASE1","title":"Study Evalutating the Pharmacokinetics (PK) and Safety of a Single Dose of Desvenlafaxine Sustained Release (DVS SR)","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2007-02","conditions":"Depressive Disorder, Major","enrollment":12},{"nctId":"NCT00300378","phase":"PHASE3","title":"Study Evaluating the Efficacy and Safety of Desvenlafaxine Tablets in Adult Outpatients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2006-03","conditions":"Depressive Disorder, Major","enrollment":480},{"nctId":"NCT00369434","phase":"PHASE3","title":"Study of the Safety and Efficacy of Desvenlafaxine Succinate for Vasomotor Symptoms in Postmenopausal Women","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2006-06","conditions":"Menopause, Vasomotor System","enrollment":450},{"nctId":"NCT00452595","phase":"PHASE3","title":"Study Evaluating DVS-233 for Treatment of Outpatients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2004-01","conditions":"Major Depressive Disorder","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["DVS-233 SR, Pristiq","Pristiq"],"phase":"marketed","status":"active","brandName":"desvenlafaxine succinate sustained release","genericName":"desvenlafaxine succinate sustained release","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Desvenlafaxine inhibits the reuptake of serotonin and norepinephrine in the central nervous system, increasing their synaptic availability. Used for Major depressive disorder, Generalized anxiety disorder, Social anxiety disorder.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}